Transformational therapy for unresectable hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-3232.20250003

Abstract

Abstract:

Hepatocellular carcinoma (HCC) is one of the common malignant tumors in China.Due to hidden early onset, most HCC patients are classified in the middle and late stages upon diagnosis.Surgical resection rate is relatively low, and conventional non-surgical treatment yields poor clinical efficacy.In recent years, with rapid development of targeted therapy and immunotherapy, transformational therapy of HCC has captivated widespread attention.Transformational therapy of HCC refers to transforming unresectable HCC into resectable HCC through local/systemic therapy and benefiting from surgical resection.In this article,research progress in transformational therapy of HCC was reviewed.

Key words: Carcinoma, hepatocellular, Conversion therapy, Targeted therapy, Immunotherapy

Zhongjing Huang, Lidong Zhang, Ziyi Wu, Junhua Ai. Transformational therapy for unresectable hepatocellular carcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 41-45.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.20250003

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2025/V14/I01/41

References 34

[1]	Sung H, Ferlay J, Siegel R L, et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2021, 71(3):209-249.
[2]	Xie DY, Zhu K, Ren ZG, et al.A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights[J].Hepatobiliary Surg Nutr, 2023, 12(2):216-228.
[3]	中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南 (2024年版)[J/OL].中华肝脏外科手术学电子杂志, 2024,13(4):407-449.
[4]	He MK, Liang RB, Zhao Y, et al.Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J].Ther Adv Med Oncol, 2021,13:17588359211002720.
[5]	Zeng H, Chen W, Zheng R, et al.Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J].Lancet Glob Health, 2018, 6(5): e555-e567.
[6]	Bai J, Huang M, Song B, et al.The current status and future prospects for conversion therapy in the treatment of hepatocellular carcinoma[J].Technol Cancer Res Treat, 2023, 22:15330338231159718.
[7]	Laface C, Fedele P, Maselli FM, et al.Targeted therapy for hepatocellular carcinoma: old and new opportunities[J].Cancers,2022, 14(16):4028.
[8]	Ouyang T, Kan X, Zheng C.Immune checkpoint inhibitors for advanced hepatocellular carcinoma: monotherapies and combined therapies[J].Front Oncol, 2022, 12:898964.
[9]	Qin S, Bi F, Gu S, et al.Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase Ⅱ-Ⅲ trial[J].J Clin Oncol, 2021, 39(27):3002-3011.
[10]	Hu L, Zheng Y, Lin J, et al.Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis[J].Clin Res Hepatol Gastroenterol, 2023, 47(1):102061.
[11]	Finn RS, Qin S, Ikeda M, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J].N Engl J Med, 2020,382(20):1894-1905.
[12]	Kudo M.Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma[J].Cancers, 2020, 12(5):1089.
[13]	Finn RS, Ikeda M, Zhu AX, et al.Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J].J Clin Oncol, 2020, 38(26):2960-2970.
[14]	闫向勇, 李俊, 牛小娟, 等.PD-1抑制剂联合靶向药物治疗晚期原发性肝癌的安全性及临床疗效观察[J].现代肿瘤医学, 2023,31(5):875-880.
[15]	Qin S, Cheng Y, Liang J, et al.Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study[J].Oncologist, 2014, 19(11):1169-1178.
[16]	林志宇, 马闻, 付榆, 等.三氧化二砷治疗中晚期原发性肝癌的近期疗效[J].中国医药指南, 2014, 12(30):28-28, 29.
[17]	况圣佳.经导管肝动脉化疗栓塞治疗对晚期肝癌患者肿瘤坏死体积及并发症的影响 [J].中国医学创新, 2022, 19(5):10-13.
[18]	Kloeckner R, Weinmann A, Prinz F, et al.Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma[J].BMC Cancer, 2015, 15:465.
[19]	中国抗癌协会肿瘤介入学专业委员会, 中国抗癌协会肿瘤介入学专业委员会化疗与免疫治疗分委会.改良式经皮肝动脉化疗药盒植入技术中国专家共识(2022版)[J].临床肝胆病杂志, 2022, 38(11):2462-2469.
[20]	Li QJ, He MK, Chen HW, et al.Hepatic arterial infusion of oxaliplatin,fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase Ⅲ trial[J].J Clin Oncol, 2022, 40(2):150-160.
[21]	Li S, Lyu N, Han X, et al.Hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: a propensity score-matching analysis[J].J Vasc Interv Radiol, 2021, 32(9):1267-1276, e1.
[22]	Wei X, Jiang Y, Zhang X, et al.Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J].J Clin Oncol, 2019, 37(24):2141-2151.
[23]	Ferini G, Palmisciano P, Scalia G, et al.The role of radiation therapy in the treatment of spine metastases from hepatocellular carcinoma:a systematic review and meta-analysis[J].Neurosurg Focus, 2022,53(5): E12.
[24]	曹磊, 廖明恒, 曾勇.肝叶增生促进技术在剩余肝体积不足肝切除中的应用 [J/OL].中华肝脏外科手术学电子杂志, 2021, 10(6):539-543.
[25]	Aoki T, Kubota K.Preoperative portal vein embolization for hepatocellular carcinoma: consensus and controversy[J].World J Hepatol, 2016, 8(9):439-445.
[26]	Huang Y, Ge W, Kong Y, et al.Preoperative portal vein embolization for liver resection: an updated meta-analysis[J].J Cancer, 2021, 12(6):1770-1778.
[27]	Wajswol E, Jazmati T, Contractor S, et al.Portal vein embolization utilizing N-butyl cyanoacrylate for contralateral lobe hypertrophy prior to liver resection: a systematic review and meta-analysis[J].Cardiovasc Intervent Radiol, 2018, 41(9):1302-1312.
[28]	陈一帆, 黄博, 卢杏生.联合肝脏离断和门静脉结扎二步肝切除术的应用进展[J].南京医科大学学报(自然科学版), 2022, 42(6):891-896.
[29]	Wang Z, Peng Y, Hu J, et al.Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: a single center study of 45 patients[J].Ann Surg, 2020, 271(3):534-541.
[30]	刘腾, 常秀娟, 何权威, 等.冷冻消融协同仑伐替尼和程序性死亡受体1单抗治疗不可切除肝细胞癌的效果及安全性分析[J].临床肝胆病杂志, 2024, 40(3):539-549.
[31]	Zhu HD, Li HL, Huang MS, et al.Transarterial chemoembolization with PD-(L)₁ inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)[J].Signal Transduct Target Ther, 2023,8(1):58.
[32]	曹耿飞, 张海潇, 顾俊鹏, 等.载药微球栓塞联合索拉非尼治疗不可切除肝癌安全性和疗效[J/OL].中华肝脏外科手术学电子杂志,2021, 10(1):43-47.
[33]	Lin LW, Ke K, Yan LY, et al.Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization[J].Front Oncol, 2023, 13:1178428.
[34]	Chiang CL, Chiu KWH, Chan KSK, et al.Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial[J].Lancet Gastroenterol Hepatol, 2023,8(2):169-178.

Please choose a citation manager

Content to export